Drug Trial Radar · NCT07840326
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Jun 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Sundance Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
Conditions
- Primary Progressive Multiple Sclerosis
- Primary Progressive MS
- Primary Progressive Multiple Sclerosis (PPMS)
- Secondary Progressive MS (SPMS)
- Secondary Progressive Multiple Sclerosis (SPMS)
- Secondary Progressive MS
- Non-Active SPMS
- Non-Active Secondary Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Interventions
SUN-627Drug
SUN-627, a once daily, orally administered, immediate release tablet
PlaceboOther
Orally-administered matched placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) compared to placeboTime frame: From enrollment to the end of study at 16 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Local Institution - Site 103
Tampa, Florida · Recruiting
Local Institution - Site 102
Atlanta, Georgia · Recruiting
Local Institution - Site 106
Stony Brook, New York · Not yet recruiting
Local Institution - Site 101
Raleigh, North Carolina · Recruiting
Local Institution - Site 104
Columbus, Ohio · Recruiting
Local Institution - Site 105
Oklahoma City, Oklahoma · Recruiting
Local Institution - Site 107
Dallas, Texas · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.